Multiepitope Peptide Vaccination in Melanoma

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: Metastatic Melanoma

Treatments: Biological: Tyrosinase, MAGE-3, GnTV

Study type: Interventional

Funder types: Other

Identifiers

NCT00153569

HaemaCBFMM03

Details and patient eligibility

About

This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Metastatic melanoma
• HLA-A1, -A2, -A24, -B44

Exclusion Criteria:

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)